CA2799205A1 - Fast results hybrid capture assay and associated strategically-truncated probes - Google Patents
Fast results hybrid capture assay and associated strategically-truncated probes Download PDFInfo
- Publication number
- CA2799205A1 CA2799205A1 CA2799205A CA2799205A CA2799205A1 CA 2799205 A1 CA2799205 A1 CA 2799205A1 CA 2799205 A CA2799205 A CA 2799205A CA 2799205 A CA2799205 A CA 2799205A CA 2799205 A1 CA2799205 A1 CA 2799205A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleic acid
- hpv
- sample
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000523 sample Substances 0.000 title claims abstract description 408
- 238000003556 assay Methods 0.000 title description 36
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 269
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 259
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 259
- 238000000034 method Methods 0.000 claims abstract description 87
- 108091033319 polynucleotide Proteins 0.000 claims description 76
- 102000040430 polynucleotide Human genes 0.000 claims description 76
- 239000002157 polynucleotide Substances 0.000 claims description 76
- 238000012217 deletion Methods 0.000 claims description 61
- 230000037430 deletion Effects 0.000 claims description 61
- 239000012472 biological sample Substances 0.000 claims description 18
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 8
- 239000002853 nucleic acid probe Substances 0.000 claims description 8
- 241000701806 Human papillomavirus Species 0.000 abstract description 239
- 238000001514 detection method Methods 0.000 abstract description 44
- 230000037029 cross reaction Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 88
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 78
- 239000003599 detergent Substances 0.000 description 78
- 239000013612 plasmid Substances 0.000 description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000011324 bead Substances 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- 230000009260 cross reactivity Effects 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 29
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 28
- 239000003153 chemical reaction reagent Substances 0.000 description 28
- 238000009396 hybridization Methods 0.000 description 28
- 239000011534 wash buffer Substances 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 230000000295 complement effect Effects 0.000 description 26
- 239000002585 base Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 22
- 239000003085 diluting agent Substances 0.000 description 22
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 238000004925 denaturation Methods 0.000 description 20
- 230000036425 denaturation Effects 0.000 description 20
- 229960003964 deoxycholic acid Drugs 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 239000000872 buffer Substances 0.000 description 16
- 230000005291 magnetic effect Effects 0.000 description 16
- 239000003391 RNA probe Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 14
- 108020004518 RNA Probes Proteins 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- -1 stool) or tissue Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002335 preservative effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000005298 paramagnetic effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000003196 chaotropic effect Effects 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000004584 polyacrylic acid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108091093088 Amplicon Proteins 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002203 pretreatment Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000012203 high throughput assay Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000321096 Adenoides Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000606153 Chlamydia trachomatis Species 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 210000002534 adenoid Anatomy 0.000 description 4
- 238000002869 basic local alignment search tool Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 229940038705 chlamydia trachomatis Drugs 0.000 description 4
- 230000001268 conjugating effect Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 239000013024 dilution buffer Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 210000004910 pleural fluid Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 108020004394 Complementary RNA Proteins 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 229920004934 Dacron® Polymers 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000224527 Trichomonas vaginalis Species 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005294 ferromagnetic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000001786 gonorrhea Diseases 0.000 description 3
- 238000013038 hand mixing Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 244000007853 Sarothamnus scoparius Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 235000019846 buffering salt Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005292 diamagnetic effect Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000005447 environmental material Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108020004996 Heterogeneous Nuclear RNA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- LRUUNMYPIBZBQH-UHFFFAOYSA-N Methazole Chemical compound O=C1N(C)C(=O)ON1C1=CC=C(Cl)C(Cl)=C1 LRUUNMYPIBZBQH-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960003431 cetrimonium Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002889 diamagnetic material Substances 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000002133 sample digestion Methods 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nuclear Medicine (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34794110P | 2010-05-25 | 2010-05-25 | |
| US61/347,941 | 2010-05-25 | ||
| PCT/US2011/037684 WO2011149897A1 (en) | 2010-05-25 | 2011-05-24 | Fast results hybrid capture assay and associated strategically-truncated probes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2799205A1 true CA2799205A1 (en) | 2011-12-01 |
Family
ID=44275651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2799205A Abandoned CA2799205A1 (en) | 2010-05-25 | 2011-05-24 | Fast results hybrid capture assay and associated strategically-truncated probes |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9376727B2 (enExample) |
| EP (1) | EP2576840B1 (enExample) |
| JP (1) | JP6153866B2 (enExample) |
| AU (1) | AU2011258501B2 (enExample) |
| CA (1) | CA2799205A1 (enExample) |
| WO (1) | WO2011149897A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009320213B2 (en) * | 2008-10-27 | 2016-06-16 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay and system |
| WO2011094514A1 (en) * | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| CN105368982B (zh) * | 2014-08-28 | 2019-01-29 | 杭州德同生物技术有限公司 | 一种高危型人乳头瘤病毒检测及分型方法 |
| CA3119710A1 (en) * | 2019-01-03 | 2020-07-09 | Hangzhou New Horizon Health Technology Co. Ltd. | Compositions and methods for detecting human papillomavirus |
Family Cites Families (223)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732847A (en) | 1981-06-09 | 1988-03-22 | University Of Hawaii | Monoclonal antibodies for DNA-RNA hybrid complexes and their uses |
| FI63596C (fi) | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser |
| US4486536A (en) | 1982-05-28 | 1984-12-04 | Smithkline Diagnostics, Inc. | Specimen slide for occult blood testing |
| US4865980A (en) | 1982-12-29 | 1989-09-12 | University Of Hawaii | Monoclonal antibodies for DNA-RNA hybrid complexes and their uses |
| US5288611A (en) | 1983-01-10 | 1994-02-22 | Gen-Probe Incorporated | Method for detecting, identifying, and quantitating organisms and viruses |
| ATE98300T1 (de) | 1983-01-10 | 1993-12-15 | Gen Probe Inc | Verfahren zum aufspueren, identifizieren und quantifizieren von organismen und viren. |
| US5200313A (en) | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
| US4743535A (en) | 1984-11-07 | 1988-05-10 | Miles Inc. | Hybridization assay employing labeled probe and anti-hybrid |
| EP0144914A3 (en) | 1983-12-12 | 1986-08-13 | Miles Inc. | Hybridization assay employing labeled pairs of hybrid binding reagents |
| US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
| FI71768C (fi) | 1984-02-17 | 1987-02-09 | Orion Yhtymae Oy | Foerbaettrade nykleinsyrareagenser och foerfarande foer deras framstaellning. |
| CA1260372A (en) | 1984-04-27 | 1989-09-26 | Elazar Rabbani | Hybridization method for the detection of genetic materials |
| CA1253777A (en) | 1984-06-01 | 1989-05-09 | Robert J. Carrico | Nucleic acid hybridization assay employing immobilized rna probes |
| US4563417A (en) | 1984-08-31 | 1986-01-07 | Miles Laboratories, Inc. | Nucleic acid hybridization assay employing antibodies to intercalation complexes |
| US4689294A (en) | 1984-11-19 | 1987-08-25 | Miles Laboratories, Inc. | Enhancement of hybridization of nucleic acids by anionic polymers |
| US5876922A (en) | 1985-07-31 | 1999-03-02 | Institute Pasteur | Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections |
| US5411857A (en) | 1985-07-31 | 1995-05-02 | Institut Nationale De La Sante | Probes for papillomaviruses and an in vitro diagnostic procedure for papilloma infections |
| CA1276575C (fr) | 1984-11-30 | 1990-11-20 | Sylvie Beaudenon | Sondes a papillomavirus et procede de diagnostic in vitro d'infections a papillomavirus |
| ES8707343A1 (es) | 1985-06-13 | 1987-07-16 | Amgen | Un metodo para aislar una secuencia de acido nucleico objetivo seleccionada |
| US4751177A (en) | 1985-06-13 | 1988-06-14 | Amgen | Methods and kits for performing nucleic acid hybridization assays |
| US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
| KR930007580B1 (ko) | 1986-03-21 | 1993-08-13 | 엥스띠뛰 빠스뙤르 | 유두종 비루스 게놈으로부터 유도된 결정 dna 서열, 그의 시험관내 진단 목적용 용도 및 항원 조성물의 제조 방법 |
| US5750338A (en) | 1986-10-23 | 1998-05-12 | Amoco Corporation | Target and background capture methods with amplification for affinity assays |
| EP0272009B2 (en) | 1986-11-24 | 2007-10-03 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| AU619170B2 (en) | 1987-01-09 | 1992-01-23 | Abbott Laboratories | Diagnostic assays using nucleic acid probes |
| ATE121794T1 (de) | 1987-02-26 | 1995-05-15 | Univ Sydney | Verfahren zum nachweis des karzinogenen menschlichen papillomavirus. |
| AU601021B2 (en) | 1987-03-11 | 1990-08-30 | Molecular Diagnostics, Inc. | Assay for necleic acid sequences in a sample |
| IL85551A0 (en) | 1987-04-01 | 1988-08-31 | Miles Inc | Rapid hybridization assay and reagent system used therein |
| DE3722968A1 (de) | 1987-07-11 | 1989-01-19 | Behringwerke Ag | Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine |
| US5656731A (en) | 1987-10-15 | 1997-08-12 | Chiron Corporation | Nucleic acid-amplified immunoassay probes |
| US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
| DE68916671T2 (de) | 1988-03-18 | 1995-03-02 | Baylor College Medicine | Mutationsnachweis durch kompetitiven Oligonukleotid-Priming. |
| US5374524A (en) | 1988-05-10 | 1994-12-20 | E. I. Du Pont De Nemours And Company | Solution sandwich hybridization, capture and detection of amplified nucleic acids |
| FR2632956B2 (fr) | 1988-05-13 | 1991-07-12 | Pasteur Institut | Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus |
| NO165894C (no) | 1988-05-24 | 1991-04-24 | Gunnar Paulsen | Analysemetode for gener. |
| DE3826793A1 (de) | 1988-08-06 | 1990-03-08 | Behringwerke Ag | Humaner papillomvirus typ 57, seine dna und die davon kodierten proteine |
| US5447839A (en) | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| US5639871A (en) | 1988-09-09 | 1997-06-17 | Roche Molecular Systems, Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| US5182377A (en) | 1988-09-09 | 1993-01-26 | Hoffmann-La Roche Inc. | Probes for detection of human papillomavirus |
| DE3856224T2 (de) | 1988-09-29 | 1998-12-03 | Chiron Corp., Emeryville, Calif. | Nachweis eines Polynukleotids durch Ersätzung einer Kette an einer Fangsonde |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5077192A (en) | 1988-10-25 | 1991-12-31 | The General Hospital Corporation | Method of detecting antigenic, nucleic acid-containing macromolecular entities |
| CA1339729C (en) | 1988-10-26 | 1998-03-17 | Wayne D. Lancaster | Human papillomavirus type 52 dna sequences and methods for employing thesame |
| DE3838269A1 (de) | 1988-11-11 | 1990-05-17 | Behringwerke Ag | Nachweis humaner papillomavirus dna und ihrer expression in zervix-abstrichen |
| EP0463036B1 (en) | 1989-03-10 | 1995-02-22 | Amoco Corporation | Immobilized oligonucleotide probes and uses therefor |
| US5106727A (en) | 1989-04-27 | 1992-04-21 | Life Technologies, Inc. | Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers |
| US5863717A (en) | 1989-11-03 | 1999-01-26 | Abbott Laboratories | Use of conserved oligonucleotide primers to amplify human papillomavirus DNA sequences |
| AU6966991A (en) | 1989-12-01 | 1991-06-26 | Gene-Trak Systems | Detection of hpv transcripts |
| US5580970A (en) | 1989-12-01 | 1996-12-03 | Amoco Corporation | Detection of HPV transcripts |
| US6174870B1 (en) | 1989-12-04 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of papillomavirus |
| US5756282A (en) | 1989-12-04 | 1998-05-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for the diagnosis of papillomavirus |
| US5811232A (en) | 1989-12-04 | 1998-09-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides for Papillomavirus |
| NL9000134A (nl) | 1990-01-19 | 1991-08-16 | Stichting Res Fonds Pathologie | Primers en werkwijze voor het detecteren van humaan papilloma virus genotypen m.b.v. pcr. |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| CA2039517C (en) | 1990-04-03 | 2006-11-07 | David Segev | Dna probe signal amplification |
| US5695926A (en) | 1990-06-11 | 1997-12-09 | Bio Merieux | Sandwich hybridization assays using very short capture probes noncovalently bound to a hydrophobic support |
| GB9015845D0 (en) | 1990-07-19 | 1990-09-05 | Emery Vincent C | Diagnostic method |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5484699A (en) | 1990-09-28 | 1996-01-16 | Abbott Laboratories | Nucleotide sequences useful as type specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods |
| CA2095611A1 (en) | 1990-11-14 | 1992-05-15 | Jennifer Kyoko Ishii | Non-isotopic detection of nucleic acids using a polystyrene support-based sandwich hybridization assay and compositions useful therefor |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP0566670A4 (en) | 1990-12-17 | 1993-12-08 | Idexx Laboratories, Inc. | Nucleic acid sequence detection by triple helix formation |
| FR2670797A1 (fr) * | 1990-12-20 | 1992-06-26 | Pasteur Institut | Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene. |
| US5219990A (en) | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| FR2678284B1 (fr) | 1991-06-28 | 1993-10-08 | Pasteur Institut | Sequences d'adn derivees du genome du papillomavirus hpv42, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus et a la production de compositions immunogenes. |
| US5543294A (en) | 1991-07-19 | 1996-08-06 | The Trustees Of Columbia University In The City Of New York | Polymerase chain reaction/restriction fragment length polymorphism method for the detection and typing of myobacteria |
| ES2194839T3 (es) | 1991-07-19 | 2003-12-01 | Univ Queensland | Vacuna de papilomavirus. |
| US5346811A (en) | 1991-07-22 | 1994-09-13 | Cerveceria Polar | Method and products for human papillomavirus detection |
| US5556748A (en) | 1991-07-30 | 1996-09-17 | Xenopore Corporation | Methods of sandwich hybridization for the quantitative analysis of oligonucleotides |
| JP3091492B2 (ja) | 1991-11-14 | 2000-09-25 | ダイジーン ダイアグノスティクス，インコーポレイテッド | 非放射性ハイブリダイゼーションアッセイおよびキット |
| US5981179A (en) | 1991-11-14 | 1999-11-09 | Digene Diagnostics, Inc. | Continuous amplification reaction |
| US5506105A (en) | 1991-12-10 | 1996-04-09 | Dade International Inc. | In situ assay of amplified intracellular mRNA targets |
| US5424413A (en) | 1992-01-22 | 1995-06-13 | Gen-Probe Incorporated | Branched nucleic acid probes |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| WO1994006859A1 (en) | 1992-09-15 | 1994-03-31 | The Dow Chemical Company | Impact modification of thermoplastics |
| JPH08503606A (ja) | 1992-10-09 | 1996-04-23 | アモコ・コーポレーション | 検定法 |
| EP0688366B1 (en) | 1993-01-15 | 2002-05-22 | The Public Health Research Institute Of The City Of New York, Inc. | Sensitive nucleic acid sandwich hybridization assays and kits |
| US6277570B1 (en) | 1993-04-13 | 2001-08-21 | Naxcor | Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents |
| US6495676B1 (en) | 1993-04-13 | 2002-12-17 | Naxcor | Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents |
| AU689789B2 (en) | 1993-07-23 | 1998-04-09 | Gen-Probe Incorporated | Methods for enhancing nucleic acid amplification |
| DE4331012A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik |
| US5679509A (en) | 1993-09-28 | 1997-10-21 | University Of New Mexico | Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer |
| US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
| DK145493D0 (da) | 1993-12-23 | 1993-12-23 | Dako As | Antistof |
| AUPM358894A0 (en) | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
| ATE362977T1 (de) | 1994-02-14 | 2007-06-15 | Macfarlane Burnet Ct For Medic | Nicht pathogene stämme des hiv-1 |
| AU685233B2 (en) | 1994-02-21 | 1998-01-15 | Stichting Researchfonds Pathologie | Human papilloma virus detection in a nucleic acid amplification process using general primers |
| DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| AUPM566794A0 (en) | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
| US6045995A (en) | 1994-08-24 | 2000-04-04 | Isis Pharmaceuticals, Inc. | Capillary electrophoretic detection of nucleic acids |
| US5622822A (en) | 1994-09-13 | 1997-04-22 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using polyethyleneimine and an anionic phosphate ester surfactant and amplification of same |
| US5582988A (en) | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
| CA2200582C (en) | 1994-09-22 | 2007-03-27 | Merck & Co., Inc. | Dna encoding human papillomavirus type 6a |
| JP3093116B2 (ja) | 1994-09-30 | 2000-10-03 | 株式会社豊田中央研究所 | 核酸検出方法 |
| GB9420146D0 (en) | 1994-10-06 | 1994-11-23 | Cancer Res Campaign Tech | Papillomavirus vaccine |
| US6057099A (en) | 1994-12-02 | 2000-05-02 | Intelligene Ltd. | Detection of nucleic acid sequences |
| US20030104361A1 (en) | 1997-09-29 | 2003-06-05 | Susan Weininger | Method of detection of nucleic acids with a specific sequence composition |
| US5731153A (en) | 1996-08-26 | 1998-03-24 | The Regents Of The University Of California | Identification of random nucleic acid sequence aberrations using dual capture probes which hybridize to different chromosome regions |
| US5888724A (en) | 1995-02-17 | 1999-03-30 | The Trustees Of Columbia University In The City Of New York | Detection of high oncogenic-risk papilloma virus in high grade cervical lesions and cancers by a PCR/ELISA assay |
| DE19506561C1 (de) | 1995-02-24 | 1996-10-10 | Deutsches Krebsforsch | Verfahren zur Früherkennung von HPV-assoziierten Karzinomen bzw. von hochgradigen, durch HPV-verursachten Dysplasien |
| US5820870A (en) | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
| US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| IL117591A0 (en) | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| US6458940B2 (en) | 1995-06-06 | 2002-10-01 | Hybridon, Inc. | HPV-specific oligonucleotides |
| US6509149B2 (en) | 1995-06-06 | 2003-01-21 | Hybridon, Inc. | HPV-specific oligonucleotides |
| WO1996040992A2 (en) | 1995-06-07 | 1996-12-19 | Abbott Laboratories | Probe masking method of reducing background in an amplification reaction |
| DE19526386C1 (de) | 1995-07-19 | 1997-01-02 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| FR2737502B1 (fr) | 1995-07-31 | 1997-10-24 | Genset Sa | Procede de detection d'acides nucleiques utilisant des sondes nucleotidiques permettant a la fois une capture specifique et une detection |
| WO1997018334A2 (en) | 1995-11-15 | 1997-05-22 | Gen-Probe Incorporated | Nucleic acid probes complementary to human papillomavirus nucleic acid and related methods and kits |
| US5888736A (en) | 1995-12-22 | 1999-03-30 | Visible Genetics, Inc. | Method, compositions and kit for detection and identification of microorganisms |
| CA2244891C (en) | 1996-02-09 | 2008-12-30 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US6852487B1 (en) | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US5981173A (en) | 1996-02-14 | 1999-11-09 | Institut Pasteur | Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39 |
| US6511805B1 (en) | 1996-03-15 | 2003-01-28 | The Penn State Research Foundation | Methods for detecting papillomavirus DNA in blood plasma and serum |
| US6214555B1 (en) | 1996-05-01 | 2001-04-10 | Visible Genetics Inc. | Method compositions and kit for detection |
| WO1998001148A1 (en) | 1996-07-09 | 1998-01-15 | President And Fellows Of Harvard College | Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein |
| US6218105B1 (en) | 1996-07-19 | 2001-04-17 | Kathleen S. Hall | High throughput papilloma virus in vitro infectivity assay |
| US5853993A (en) | 1996-10-21 | 1998-12-29 | Hewlett-Packard Company | Signal enhancement method and kit |
| US6265154B1 (en) | 1996-10-25 | 2001-07-24 | Abbott Laboratories | Nucleic acid primers and probes for detecting oncogenic human papillomaviruses |
| US6117631A (en) | 1996-10-29 | 2000-09-12 | Polyprobe, Inc. | Detection of antigens via oligonucleotide antibody conjugates |
| GB9624165D0 (en) | 1996-11-19 | 1997-01-08 | Amdex A S | Use of nucleic acids bound to carrier macromolecules |
| DE19648962C1 (de) | 1996-11-26 | 1998-02-26 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US6388065B1 (en) | 1996-11-27 | 2002-05-14 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | DNA for evaluating the progression potential of cervical lesions |
| US6110676A (en) | 1996-12-04 | 2000-08-29 | Boston Probes, Inc. | Methods for suppressing the binding of detectable probes to non-target sequences in hybridization assays |
| US20020034737A1 (en) | 1997-03-04 | 2002-03-21 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
| DE19712541C1 (de) | 1997-03-25 | 1998-11-05 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US5843995A (en) | 1997-07-07 | 1998-12-01 | University Of Medicine And Dentistry Of New Jersey | Inhibition of HIV-1 replication using oligocarbamate derivatives |
| DE19735118C1 (de) | 1997-08-13 | 1998-08-13 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| EP1201771A3 (en) | 1997-09-16 | 2002-10-23 | Innogenetics N.V. | Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization |
| US6013258A (en) | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| JP2002505071A (ja) | 1997-11-04 | 2002-02-19 | ロシュ ダイアグノスティックス ゲーエムベーハー | 特異的かつ高感度な核酸検出方法 |
| BR9814271A (pt) | 1997-12-12 | 2001-03-20 | Digene Corp | Determinação de doenças relacionadas com o vìrus do papiloma humano |
| US20030096232A1 (en) | 1997-12-19 | 2003-05-22 | Kris Richard M. | High throughput assay system |
| EP1865074B1 (en) | 1997-12-22 | 2011-04-20 | Hitachi Chemical Co., Ltd. | Direct RT-PCR on oligonucleotide-immobilized PCR microplates |
| EP1047794A2 (en) | 1998-01-13 | 2000-11-02 | BioChip Technologies GmbH | Method for the detection or nucleic acid of nucleic acid sequences |
| US5994079A (en) | 1998-02-06 | 1999-11-30 | Digene Corporation | Direct detection of RNA mediated by reverse transcriptase lacking RNAse H function |
| US7399589B2 (en) | 1998-02-06 | 2008-07-15 | Digene Corporation | Immunological detection of RNA:DNA hybrids on microarrays |
| US6686151B1 (en) | 1998-02-06 | 2004-02-03 | Digene Corporation | Immunological detection of RNA:DNA hybrids on microarrays |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| EP0945627B1 (en) | 1998-03-23 | 2004-01-02 | SPAL S.r.l. | Axial flow fan |
| US6183956B1 (en) | 1998-03-31 | 2001-02-06 | Tularik, Incorporated | High throughput in vitro screening assays for transcription modulators |
| US6045993A (en) | 1998-05-30 | 2000-04-04 | Visible Genetics Inc. | Method, reagent and kit for genotyping of human papillomavirus |
| US6284532B1 (en) | 1998-08-17 | 2001-09-04 | Indiana University | Purified human papillomavirus |
| DE19840263C1 (de) | 1998-09-03 | 2000-05-25 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| CA2342289C (en) | 1998-09-04 | 2012-07-24 | Aventis Pasteur Limited | Treatment of cervical cancer |
| US7569344B2 (en) | 1998-10-26 | 2009-08-04 | Ventana Medical Systems, Inc. | Detection of human papilloma virus in papanicolaou (Pap) smears |
| US6951722B2 (en) | 1999-03-19 | 2005-10-04 | Takara Bio Inc. | Method for amplifying nucleic acid sequence |
| US20010055766A1 (en) | 1999-04-02 | 2001-12-27 | Alexander Aristarkhov | Immunosorbant assay using branched bis-biotin/avidin/multiple label complex as a detection reagent |
| AU4051300A (en) | 1999-04-02 | 2000-10-23 | Tropix, Inc. | High throughput and high sensitivity detection assays |
| NZ514662A (en) | 1999-04-07 | 2004-01-30 | Sankyo Co | Amine derivatives |
| US6544732B1 (en) | 1999-05-20 | 2003-04-08 | Illumina, Inc. | Encoding and decoding of array sensors utilizing nanocrystals |
| US6420106B1 (en) | 1999-06-09 | 2002-07-16 | Quantovir Ab | Method and kit for early cancer prediction |
| US6200746B1 (en) | 1999-08-25 | 2001-03-13 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| US20060275784A1 (en) | 1999-10-26 | 2006-12-07 | Ventana Medical Systems, Inc. | Detection of Human Papilloma Virus in Papanicolaou (Pap) Smears |
| US6893819B1 (en) | 2000-11-21 | 2005-05-17 | Stratagene California | Methods for detection of a nucleic acid by sequential amplification |
| DE10009143B4 (de) | 2000-02-26 | 2012-04-26 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Nachweis von Humanen Papillomviren |
| KR100382703B1 (ko) | 2000-03-15 | 2003-05-09 | 주식회사 바이오메드랩 | 인유두종바이러스의 유전형 진단키트 및 상기 진단키트의제조방법 |
| US6936443B2 (en) | 2000-04-03 | 2005-08-30 | Cytyc Corporation | Detection and typing of human papillomavirus using PNA probes |
| US7510834B2 (en) | 2000-04-13 | 2009-03-31 | Hidetoshi Inoko | Gene mapping method using microsatellite genetic polymorphism markers |
| AU2001274869A1 (en) | 2000-05-20 | 2001-12-03 | The Regents Of The University Of Michigan | Method of producing a dna library using positional amplification |
| US6331423B1 (en) | 2000-06-01 | 2001-12-18 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| ATE364722T1 (de) | 2000-06-02 | 2007-07-15 | Bayer Corp | Verfahren zum nachweis und zur lokalisierung von genen in situ durch hybridisierung einer verzweigten dna |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US20030165843A1 (en) | 2000-07-28 | 2003-09-04 | Avi Shoshan | Oligonucleotide library for detecting RNA transcripts and splice variants that populate a transcriptome |
| US6329152B1 (en) | 2000-11-30 | 2001-12-11 | Bruce K. Patterson | Process for detecting low abundance RNA in intact cells |
| EP1351970A2 (en) | 2000-12-12 | 2003-10-15 | Invitrogen Corporation | Compositions and methods for the release of nucleic acid molecules from solid matrices |
| EP2363476B1 (en) | 2001-02-16 | 2013-05-29 | Promega Corporation | Magnetic isolation and purification of nucleic acids |
| US6670150B1 (en) | 2001-05-10 | 2003-12-30 | Applera Corporation | Isolated human receptor proteins, nucleic acid molecules encoding human receptor proteins, and uses thereof |
| US6884605B2 (en) | 2001-08-09 | 2005-04-26 | Board Of Trustees Of The University Of Arkansas | Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer |
| SI1421200T1 (sl) | 2001-08-23 | 2007-04-30 | Merck & Co Inc | Poskusi PCR fluorescentnih multipleks HPV-jev z uporabo vec fluoroforov |
| KR100452163B1 (ko) | 2001-09-14 | 2004-10-12 | 주식회사 바이오메드랩 | 인유두종 바이러스의 감염을 진단하기 위한 유전형 분석키트 |
| US20050032105A1 (en) | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
| US6977148B2 (en) | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
| WO2003057914A2 (en) | 2002-01-07 | 2003-07-17 | Norchip A/S | METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS mRNA |
| AU2003217413A1 (en) | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
| HUP0200981A3 (en) | 2002-03-14 | 2004-06-28 | Genoid Kft | Pcr reactions with hybridizing probes using primers with broad genotype-specificity for detection of human papilloma-viruses and typing amplificates by using specifically hybridizing oligonucleotides |
| EP1499749B1 (en) | 2002-04-16 | 2008-04-09 | Autogenomics, Inc. | Human papilloma virus detection with dna microarray |
| SI1506222T1 (sl) | 2002-05-17 | 2009-10-31 | Universty Of Cape Town | Himerni L1-proteini humanega papilomavirusa 16, ki obsegajo L2-peptid, delci, podobni virusu, pripravljeni iz njih, in postopek za pripravo delcev |
| WO2004002416A2 (en) | 2002-06-26 | 2004-01-08 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
| SE0202896D0 (sv) | 2002-10-01 | 2002-10-01 | Quantovir Ab | Method for estimating the risk of carcinoma development |
| EP1553966B1 (en) | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| ZA200506094B (en) | 2002-12-31 | 2006-11-29 | Mmi Genomics Inc | Compositions, methods and systems for inferring bovine traits |
| KR101080628B1 (ko) | 2003-03-24 | 2011-11-08 | 머크 샤프 앤드 돔 코포레이션 | 효모에서 ｈｐｖ 31 ｌ1의 최적 발현 |
| EP1613771B1 (en) | 2003-04-04 | 2012-03-21 | Roche Diagnostics GmbH | Improved system for multi color real time pcr |
| US7129260B2 (en) | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| US20040248107A1 (en) | 2003-06-09 | 2004-12-09 | Sokolova Irina A. | Detection of high grade dysplasia in cervical cells |
| JP5183063B2 (ja) | 2003-07-05 | 2013-04-17 | ザ ジョンズ ホプキンス ユニバーシティ | 遺伝的変異の検出および列挙のための方法ならびに組成物 |
| DE60300339T2 (de) | 2003-08-25 | 2006-04-13 | Mtm Laboratories Ag | Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben |
| JP4498357B2 (ja) | 2003-09-25 | 2010-07-07 | サード・ウェーブ・テクノロジーズ・インク | Ｈｐｖの検出法 |
| MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| WO2005033333A2 (en) * | 2003-10-07 | 2005-04-14 | Dako Denmark A/S | Methods and compositions for the diagnosis of cancer |
| US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| JP2005243132A (ja) | 2004-02-26 | 2005-09-08 | Renesas Technology Corp | 半導体装置 |
| RU2373219C2 (ru) | 2004-03-24 | 2009-11-20 | Мерк энд Ко. Инк. | Оптимизированная экспрессия hpv 52 l1 в дрожжах |
| CN1690223B (zh) | 2004-04-27 | 2010-05-05 | 亚能生物技术（深圳）有限公司 | 人乳头瘤病毒分型基因芯片检测系统 |
| US7482142B1 (en) | 2004-05-07 | 2009-01-27 | Roche Molecular Systems, Inc. | High-risk human papillomavirus detection |
| EP1794319B1 (en) | 2004-09-30 | 2014-08-13 | Epigenomics AG | Method for providing dna fragments derived from an archived sample |
| US7670774B2 (en) | 2004-10-04 | 2010-03-02 | Goodgene Inc. | Probe of human papillomavirus and DNA chip comprising the same |
| WO2006063065A2 (en) | 2004-12-08 | 2006-06-15 | Gen-Probe Incorporated | Detection of nucleic acids from multiple types of human papillomaviruses |
| AU2006205638A1 (en) | 2005-01-14 | 2006-07-20 | The Regents Of The University Of Michigan | Systems, methods, and compositions for detection of human papilloma virus in biological samples |
| US20060240449A1 (en) | 2005-01-19 | 2006-10-26 | Mcglennen Ronald C | Methods and compositions for preparation of biological samples |
| US7524631B2 (en) | 2005-02-02 | 2009-04-28 | Patterson Bruce K | HPV E6, E7 mRNA assay and methods of use thereof |
| CA2602185A1 (en) | 2005-04-06 | 2006-10-06 | Verenium Corporation | Enzymes and formulations for broad-specificity decontamination of chemical and biological warfare agents |
| WO2006124771A2 (en) | 2005-05-12 | 2006-11-23 | Panomics, Inc. | Multiplex branched-chain dna assays |
| US20080003565A1 (en) | 2006-05-02 | 2008-01-03 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Viral nucleic acid microarray and method of use |
| WO2007134252A1 (en) | 2006-05-11 | 2007-11-22 | Becton, Dickinson And Company | Method of protein extraction from cells |
| WO2008139938A1 (ja) | 2007-05-02 | 2008-11-20 | National University Corporation Tokyo Medical And Dental University | ヒトパピローマウイルス１６型遺伝子を標的とする二本鎖核酸分子及びそれを含む医薬 |
| LT3101141T (lt) | 2007-06-08 | 2020-03-10 | Epigenomics Ag | Metilinimo analizės būdas |
| CN101177701B (zh) | 2007-09-29 | 2010-08-18 | 潮州凯普生物化学有限公司 | 人乳头状瘤病毒基因分型检测试剂盒及其基因芯片制备方法 |
| JP2009106220A (ja) | 2007-10-31 | 2009-05-21 | Genodive Pharma Kk | 基板上での等温増幅反応による標的塩基配列の捕捉及び検出方法 |
| PT2209920T (pt) | 2007-11-01 | 2016-08-02 | Self-Screen B V | Método inovador de deteção para hpvs cervicais |
| US20110027798A1 (en) | 2008-03-31 | 2011-02-03 | The Ohio State University Research Foundation | Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides |
| WO2010004251A1 (en) | 2008-06-16 | 2010-01-14 | Oncomethylome Sciences Sa | Dna methylomes |
| US20100121046A1 (en) | 2008-09-05 | 2010-05-13 | Mayo Foundation For Medical Education And Research | Collecting and processing complex macromolecular mixtures |
| US9090948B2 (en) | 2008-09-30 | 2015-07-28 | Abbott Molecular Inc. | Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples |
| AU2009320213B2 (en) * | 2008-10-27 | 2016-06-16 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay and system |
| EP2184368A1 (en) | 2008-11-07 | 2010-05-12 | DKFZ Deutsches Krebsforschungszentrum | Diagnostic transcript and splice patterns of HPV16 in different cervical lesions |
| EP2425019B1 (en) | 2009-05-01 | 2014-03-19 | QIAGEN Gaithersburg, Inc. | A non-target amplification method for detection of rna splice-forms in a sample |
-
2011
- 2011-05-24 AU AU2011258501A patent/AU2011258501B2/en not_active Ceased
- 2011-05-24 US US13/114,344 patent/US9376727B2/en not_active Expired - Fee Related
- 2011-05-24 JP JP2013512140A patent/JP6153866B2/ja not_active Expired - Fee Related
- 2011-05-24 EP EP11726003.4A patent/EP2576840B1/en not_active Not-in-force
- 2011-05-24 CA CA2799205A patent/CA2799205A1/en not_active Abandoned
- 2011-05-24 WO PCT/US2011/037684 patent/WO2011149897A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2576840A1 (en) | 2013-04-10 |
| EP2576840B1 (en) | 2018-10-17 |
| JP6153866B2 (ja) | 2017-06-28 |
| AU2011258501B2 (en) | 2016-07-07 |
| US9376727B2 (en) | 2016-06-28 |
| JP2013534810A (ja) | 2013-09-09 |
| US20120004128A1 (en) | 2012-01-05 |
| AU2011258501A1 (en) | 2013-01-10 |
| WO2011149897A1 (en) | 2011-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8877436B2 (en) | Fast results hybrid capture assay on an automated platform | |
| JP6104296B2 (ja) | 標的核酸の存在を判別するための合成プローブを用いた組成物、方法、およびキット | |
| US9689047B2 (en) | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids | |
| AU2012220575A1 (en) | Materials and methods for detection of HPV nucleic acid | |
| EP2529031B1 (en) | Method of determining and confirming the presence of hpv in a sample | |
| AU2011258501B2 (en) | Fast results hybrid capture assay and associated strategically-truncated probes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150827 |
|
| FZDE | Discontinued |
Effective date: 20190904 |